Please ensure Javascript is enabled for purposes of website accessibility

This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?

By Alex Carchidi - Jun 9, 2021 at 11:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The income could be a slow burn.

Though it's rarely a relevant factor for healthcare investors, it's a no-brainer that certain raw materials are necessary to manufacture medicines, just as they are with nearly everything else. And for something like a coronavirus vaccine intended for worldwide distribution, bottlenecks in the capacity to produce raw materials like lipids can be a massive problem. So, a company that solves the bottleneck has the potential to make a tidy pile of cash.

And that's exactly why, in late May, the German pharma giant Merck Kommanditgesellschaft auf Aktien (MRK -1.87%) -- not to be confused with the American pharma giant Merck & Co. -- announced that its new synthetic lipid product is ready to sell. These lipids are a core ingredient of the mRNA coronavirus vaccines being made by companies like Pfizer and BioNTech, both of which are already its customers for similar products. Will the timely new product position Merck KGaA as an upstream supplier for the entire mRNA medicine world and allow it to reap the benefits, or is it unlikely to reward shareholders?

Four chemists examine a clipboard with data while standing in their laboratory.

Image source: Getty Images.

Why lipids matter

To start, let's quickly review the scientific concepts at hand so that it's clear why Merck KGaA's new product is worth knowing about. As you may know, lipid molecules don't dissolve in water. That's a useful property to have, because it means that they don't dissolve in the watery environment of the cells in a human body. So, for medical purposes, other molecules can be enclosed inside a lipid bubble, which protects those molecules from dissolving too. Then, the lipid bubble can fuse with a person's cells, dumping its payload right where it needs to be to have the desired effect.

Drugmakers have spent many years and many millions of dollars to develop complex drug delivery systems based on heavily modified lipids. For an especially fragile payload like mRNA in certain coronavirus vaccines, having a steady, high-quality supply of basic lipids is indispensable. But, before the pandemic, there wasn't such urgent demand for them, and so there wasn't much manufacturing capacity to tap into once mRNA vaccine makers needed it. That's where Merck KGaA comes in.

It isn't the first company to make a synthetic lipid intended for use with medicines, though it might be the only one with the production capacity needed to actually meet the amount of demand from vaccine manufacturers. And, because it prepared the new lipid product a stunning nine months ahead of schedule, it's ready to capitalize on demand right when it's at a peak. Given that mRNA medicines are likely just beginning their time in the global limelight, it's highly probable that Merck KGaA will be making money by selling lipids for years to come.

Don't put in a buy order just yet

Nonetheless, there's one issue that should give investors pause.

Trailing 12-month revenue for this company is $21.74 billion. For the new lipid sales to make a big enough contribution to its revenue to cause the stock to grow immediately, Merck KGaA would need to be making billions of dollars. Even its largest customers don't need that many lipids. In the last 12 months, BioNTech's cost of revenue was $347.93 million, which undoubtedly includes far more than raw-material costs alone. So, the new lipid revenue is far more likely to be an incremental addition to Merck KGaA's income than it is to be a revolutionary addition.

On the other hand, there's still no data about Merck KGaA's new sales volume for lipids, and there hasn't been a quarterly report that accounts for any of the additional revenue. To me, that means it's a bit premature to rush to buy the stock right now.

The next investor update will be on Aug. 5, when the second-quarter earnings report drops. While management might not even mention the exact impact of the lipid products, be sure to keep an eye on the top line. If revenue grows faster than the plodding pace that's the company's norm, there's a good chance that the new inflows will become a lasting feature, and that might make it worth a purchase.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MERCK Kommanditgesellschaft auf Aktien Stock Quote
MERCK Kommanditgesellschaft auf Aktien
MRK
$183.60 (-1.87%) $-3.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.